Louis J. Lavigne, Jr., Former EVP & CFO of Genentech, Joins DocuSign Board of Directors
Lavigne Brings 30 Years of Financial Management Experience to Docusign’s Audit & Finance Committee
SAN FRANCISCO, CA & ASPEN, CO – FORTUNE BRAINSTORM TECH – July 23, 2013 – DocuSign, The Global Standard for eSignature®, announced that Louis J. Lavigne, Jr., former Executive Vice President and Chief Financial Officer of Genentech Inc., has joined DocuSign’s board of directors and will lead its Audit and Finance Committee. Lavigne brings decades of corporate finance, accounting, growth strategy, and IT management experience to DocuSign’s board. In his twenty-three years at Genentech, Lavigne led the company’s financial, corporate relations, and information technology groups as revenues grew from $40 million in 1983 to $300 million in 1988 when he became CFO to more than $6.5 billion in 2005 when he was named ‘Best CFO in Biotech’ by Institutional Investor.
“I’m excited to join DocuSign’s board because the company provides such valuable solutions to healthcare, bio-science, and so many other important industries, and is led by a dynamic growth team,” said Lavigne. “DocuSign’s focus on innovation is resulting in a huge, quickly growing DocuSign Global Network that delivers faster, mobile, and more convenient digital experiences for everyone.”
Following his participation on today’s Fortune Brainstorm Tech panel, Fueling Growth with Talent, DocuSign chairman and CEO Keith Krach said, “I’m happy to welcome Lou to our board. We’re fortunate that our innovative services not only attract 60,000 new users per day, but also the best and brightest talent like Lou to our team.”
Lavigne is a member of the board of directors of Accuray, Inc. (chairman of the board & Compensation Committee), Allergan, Inc. (member of the Audit and Finance & Science and Technology Committees), BMC Software (chairman of the Audit Committee & member of the M&A Committee), Depomed, Inc. (Audit Committee member), NovoCure (Audit Committee chairman) and SafeNet, Inc. (Audit Committee chairman). Previously he was a director and chairman of the Audit Committee of several other public companies including Arena Pharmaceuticals, Equinix, Kyphon, and Xenova. Lavigne is also part of the Pacific SW Audit Committee Network of Audit Committee Chairs and Deloitte's Life Sciences Advisory Board.
DocuSign’s legally binding, secure, SaaS-based platform allows consumers and businesses of all sizes and industries to collect information and sign documents online – eliminating the hassles, costs, and lack of security of printing, faxing, scanning, and overnighting documents to capture information and signatures. DocuSign helps companies automate and streamline their business processes to create better customer experiences and save money. Companies interested in learning more about DocuSign may visit http://www.docusign.com.
About DocuSign Inc.
DocuSign® is the leader in eSignature transaction management and the global standard for eSignature. Global enterprises, business departments, individual professionals and consumers are standardizing on DocuSign, with more than 60,000 new users joining the DocuSign Global Network every day. Today, that network includes more than 40 million users in 188 countries. DocuSign is used to accelerate transaction times to increase speed to results, reduce costs, and delight customers across nearly every industry – from financial services, insurance, technology, healthcare, manufacturing, communications, property management and consumer goods, to higher education and others. For more information, visit www.docusign.com or call 877.720.2040. Visit the DocuSign blog at www.docusign.com/blog and follow DocuSign on Twitter, LinkedIn and Facebook.